Casey C. Kopczynski
2018
In 2018, Casey C. Kopczynski earned a total compensation of $2.3M as Chief Scientific Officer at Aerie Pharmaceuticals, a 17% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $161,850 |
|---|---|
| Option Awards | $1,339,321 |
| Salary | $415,000 |
| Stock Awards | $428,400 |
| Other | $1,183 |
| Total | $2,345,754 |
Kopczynski received $1.3M in option awards, accounting for 57% of the total pay in 2018.
Kopczynski also received $161.9K in non-equity incentive plan, $415K in salary, $428.4K in stock awards and $1.2K in other compensation.
Rankings
In 2018, Casey C. Kopczynski's compensation ranked 4,946th out of 14,244 executives tracked by ExecPay. In other words, Kopczynski earned more than 65.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,946 out of 14,244 | 65th |
Division Manufacturing | 1,861 out of 5,759 | 68th |
Major group Chemicals And Allied Products | 681 out of 2,122 | 68th |
Industry group Drugs | 570 out of 1,811 | 69th |
Industry Biological Products, Except Diagnostic Substances | 116 out of 339 | 66th |
Source: SEC filing on April 10, 2019.
Kopczynski's colleagues
We found four more compensation records of executives who worked with Casey C. Kopczynski at Aerie Pharmaceuticals in 2018.
News
Aerie Pharmaceuticals CEO Vicente Anido's 2021 pay rises 4% to $3.8M
April 26, 2022
Aerie Pharmaceuticals CEO Vicente Anido's 2020 pay falls 35% to $3.6M
April 27, 2021
Aerie Pharmaceuticals CEO Vicente Anido's 2019 pay slips 18% to $5.5M
April 24, 2020
Aerie Pharmaceuticals CEO Vicente Anido's 2018 pay falls 33% to $6.8M
April 10, 2019